Aromatase inhibition in advanced prostatic cancer: preliminary communication.
We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained sig...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
1990
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971817/ |